Alpha Teknova, Inc. · NASDAQ:TKNO
Alpha Teknova — Q3 2025 Earnings Presentation
19 slides from Alpha Teknova's earnings presentation, Nov 6, 2025
Slide 1: Financial Results: Q3:2025 Slide Supplement
FINANCIAL RESULTS: Q3:2025 SLIDE SUPPLEMENT Nasdaq: TKNO November 6, 2025
Slide 2: Today's Agenda
Today’s Agenda • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A © 2025 Alpha Teknova, Inc. ● Financial Results | Q3:2025 ● Slide Supplement November 6, 2025 2
Slide 3: Forward-looking statements and use of non-GAAP financial measures
Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, b
Slide 4: Business Highlights and Updates
Business Highlights and Updates STEPHEN GUNSTREAM President and Chief Executive Officer
Slide 5: Our path to sustainable, above-market growth
Our path to sustainable, above-market growth ESTABLISH INVEST SCALE 1996-2016 2017-2023 2024+ • Built scientific and • Received ISO 13485:2016 certification • Sustainable above- operational know-how market revenue growth • Secured capital to drive investments and • Established high-quality positione
Slide 6: Revenue by Product Type and End Market
2024 BREAKDOWN Revenue by Product Type and End Market OTHER Total 2024 Revenue by Product~5% Type and End Market 2024 REVENUE BREAKDOWN • Catalog: ~60% of 2024 Revenue Non- § Low single-digit growth for full year Biopharma § Improved to high single-digit growth in H2:24 ~10% CUSTOM • Custom: ~35% of
Slide 7: We have been successful in migrating our customers from catalog to custom to GMP reagents
We have been successful in migrating our customers from catalog to custom to GMP reagents Relative Annual Spend by Account Type in 2024 Total Revenue by Account Type* 58% of 2024 revenue Cell and Gene Therapy Count by Account Type* 27% of 2024 revenue from custom and/or from CGT $45 clinical account
Slide 8: Financial Results and 2025 Outlook
Financial Results and 2025 Outlook MATT LOWELL Chief Financial Officer
Slide 9: Q3:2025 Revenue Highlights
Q3:2025 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $10.5 • Total second quarter revenue up $9.6 9% compared to the same period in 9% y/y $1.7 prior year $2.0 • Lab Essentials increased 16% from the same period in prior year • Clinical Solutions decreased 13% from the same period in p
Slide 10: Q3:2025 Income Statement Highlights
Q3:2025 Income Statement Highlights Gross Margin (%) Total OpEx ($M) Gross Margin was 30.7% $7.5 $7.2 29.8% excluding non- recurring, non-cash charges related to the expired and excess 0.9% inventory of ($2.8M) Q3:2024 Q3:2025 Q3:2024 Q3:2025 Adjusted EBITDA1 ($M) Diluted EPS ($) ($1.6) ($0.08) ($0.
Slide 11: Q3:2025 Cash Flow and Balance Sheet Highlights
Q3:2025 Cash Flow and Balance Sheet Highlights Capital Expenditure ($M) Free Cash Flow1 ($M) ($2.4) ($2.4) $0.4 $0.3 Q3:2024 Q3:2025 Q3:2024 Q3:2025 Cash, Cash Equivalents, and Short-Term Investment was $22.1M as of September 30, 2025 1 Free Cash Flow equals cash provided by (used in) operating acti
Slide 12: Financial Trends
Financial Trends Total OpEx ($M) Adjusted EBITDA1 ($M) ($0.8) $12.1 $12.2 ($1.6) $11.4 ($2.3) ($2.6) ($2.5) $10.2 $10.2 ($3.2) ($3.8) ($5.0) $7.9 $7.8 $8.0 ($5.5) $7.5 $7.4 $7.2 ($6.1) ($6.0) $10.7 $9.9 $9.8 $9.7 $8.9 $7.8 $7.5 $7.8 $8.0 $7.4 $7.2 Q1:23 Q2:23 Q3:23 Q4:23 Q1:24 Q2:24 Q3:24 Q4:24 Q1:2
Slide 13: 2025 Outlook
2025 Outlook • Estimate total revenue between $39–42 million, up 7% y/y at the midpoint • We are targeting Free Cash Outflow of less than $12 million for 2025 § Teknova defines Free Cash Outflow as cash used in operating activities plus purchases of property, plant, and equipment • Estimate annualiz
Slide 14: Closing Comments
Closing Comments STEPHEN GUNSTREAM President and Chief Executive Officer
Slide 15: Q&A
Q&A
Slide 16: Historical Customer Metrics by Product Category
Historical Customer Metrics by Product Category NON-GAAP FIGURES: LAB ESSENTIALS CLINICAL SOLUTIONS Number of 3,255 3,045 48 Customers1 2,754 2,826 34 2,008 21 24 13 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 Average Revenue $10,578 $10,191 $369 $352 $9,871 $9,761 $9,486 $323 per Customer1 $1
Slide 17: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 18: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2025 Alpha Teknova, Inc. ● Financial Results | Q3:2025 ● Slide Supplement November 6, 2025 18
Slide 19: teknova
teknova: